Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients

NCT01896479 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT01896479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01896479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
Lead sponsor
Exelixis
Phase
Phase 4
Overall status
Active, not recruiting
Start date
February 25, 2015
Completion date
January 31, 2035
Enrollment
247 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

medullary thyroid cancer